PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Breakthrough in asthma research • Asthma: An overview PART 05: Pipeline portfolio PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Key buying criteria for asthma drugs PART 08: Market segmentation by type of treatment • Preventive medications • Quick-relief medications • Others PART 09: Market segmentation by drug class • Combination therapies • Bronchodilators • Immunosuppressants • Leukotriene antagonists • Mast cell stabilizers PART 10: Segmentation by route of administration • Inhalation • Parenteral • Oral PART 11: Drug delivery devices market for asthma drugs • Market overview • Market segmentation by product type PART 12: Geographical segmentation • Global asthma therapeutics market by geography 2015-2020 • Asthma therapeutics market in Americas • Asthma therapeutics market in EMEA • Asthma therapeutics market in APAC PART 13: Market drivers • Huge market potential for mAbs • New product approvals minimizing the impact of generic erosion • Increasing rate of allergies due to environmental pollution PART 14: Impact of drivers PART 15: Market challenges • Increased preference for CAM • Poor patient adherence toward controller medications • Presence of different phenotypes of asthma leading to prescription errors PART 16: Impact of drivers and challenges PART 17: Market trends • Innovative technologies for drug delivery • Growing adoption of immunotherapies • Shift toward immune/inflammatory system targets from glucocorticoid and adrenergic receptors • Increase in online marketing services • Growing use of home healthcare devices PART 18: Vendor landscape • Competitive scenario • Key news PART 19: Key vendor analysis • AstraZeneca • Boehringer Ingelheim • F. Hoffmann-La Roche • GSK • Merck • Other prominent vendors PART 20: Appendix • List of abbreviations PART 21: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Breakthrough in asthma research Exhibit 03: Major diagnostic procedures for asthma Exhibit 04: Percentage share of pipeline molecules based on stage of development Exhibit 05: Pipeline portfolio: Global asthma therapeutics market Exhibit 06: Global asthma drugs market: Market overview 2015 Exhibit 07: Global asthma therapeutics market 2015-2020 ($ billions) Exhibit 08: Global asthma drugs market snapshot: Developed and emerging markets 2015 Exhibit 09: Global asthma therapeutics market: Key parameters driving the market growth 2015 Exhibit 10: Five forces analysis Exhibit 11: Key buying criteria for asthma drugs Exhibit 12: Global asthma therapeutics market: Key parameters importance Exhibit 13: Impact of key customer segments on market Exhibit 14: Segmentation of asthma drugs based on type of treatment Exhibit 15: Segmentation of asthma drugs based on drug class Exhibit 16: Percentage share of global asthma therapeutics by drug class based on revenue 2015 Exhibit 17: Global asthma therapeutics market: Drug class segmentation growth cycle analysis 2015 Exhibit 18: Combination therapies market in global asthma therapeutics market 2015-2020 ($ billions) Exhibit 19: Bronchodilators market in global asthma therapeutics market 2015-2020 ($ billions) Exhibit 20: Percentage share of allergy immunotherapies and steroids in global immunosuppressants market 2015 Exhibit 21: Immunosuppressants market in global asthma therapeutics market 2015-2020 ($ billions) Exhibit 22: Leukotriene antagonists market in global asthma therapeutics market 2015-2020 ($ billions) Exhibit 23: Mast cell stabilizers market in global asthma therapeutics market 2015-2020 ($ billions) Exhibit 24: Segmentation of global asthma therapeutics market by route of administration Exhibit 25: Global asthma drug delivery devices market 2015-2020 ($ millions) Exhibit 26: Global asthma drug delivery devices market segmentation by product type Exhibit 27: Percentage share of global asthma drug delivery devices by type 2015 Exhibit 28: Percentage share of inhalers in global asthma drug delivery devices market 2015 Exhibit 29: Inhalers market in global asthma drug-delivery devices market 2015-2020 ($ millions) Exhibit 30: Percentage share of nebulizers in global asthma drug delivery devices market 2015 Exhibit 31: Nebulizers market in global asthma drug-delivery devices market 2015-2020 ($ millions) Exhibit 32: Global asthma therapeutics market by geography 2015-2020 Exhibit 33: Percentage share of global asthma therapeutics market by geography 2015 and 2020 Exhibit 34: Global asthma therapeutics market segmentation by geography 2015-2020 ($ billions) Exhibit 35: Global share of asthma therapeutics market by geography 2015 Exhibit 36: Global asthma therapeutics market: Country analysis based on revenue and growth rate Exhibit 37: Impact of ACA act on asthma therapeutics market Exhibit 38: Asthma therapeutics market in Americas 2015-2020 ($ billions) Exhibit 39: Asthma therapeutics market: PEST analysis Exhibit 40: Prevalence of asthma in major countries of EMEA Exhibit 41: Asthma therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 42: Asthma therapeutics market in EMEA: PEST analysis Exhibit 43: Asthma therapeutics market in APAC 2015-2020 ($ billions) Exhibit 44: Asthma therapeutics market: PEST analysis Exhibit 45: mAbs approved for treatment of asthma Exhibit 46: mAbs under development for treatment of asthma Exhibit 47: Impact of drivers Exhibit 48: Use of CAM therapies among individuals in US Exhibit 49: Impact of drivers and challenges Exhibit 50: Market share of major vendors based on asthma therapeutics revenue 2015 Exhibit 51: Competitive scenario of global asthma therapeutics market vendors 2015-2020 Exhibit 52: Geographical presence of key vendors Exhibit 53: AstraZeneca: YoY revenue and growth rate of Symbicort 2013-2015 ($ billions) Exhibit 54: AstraZeneca: Geographical segmentation of Symbicort 2015 Exhibit 55: AstraZeneca: YoY revenue and growth rate of Pulmicort 2013-2015 ($ millions) Exhibit 56: AstraZeneca: Geographic segmentation of Pulmicort 2015 Exhibit 57: AstraZeneca: Metrics analysis Exhibit 58: Boehringer Ingelheim: YoY revenue and growth rate of Spiriva 2013-2015 ($ billions) Exhibit 59: Boehringer Ingelheim: Metrics analysis Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Xolair 2012-2014 ($ millions) Exhibit 61: F. Hoffmann-La Roche: Metrics analysis Exhibit 62: GSK: YoY revenue and growth rate of Seretide/Advair 2013-2015 ($ billions) Exhibit 63: Geographical segmentation of Seretide/Advair 2015 Exhibit 64: GSK: YoY revenue and growth rate of Flixotide/Flovent 2013-2015 ($ billions) Exhibit 65: GSK: Geographical segmentation of Flixotide/Flovent 2015 Exhibit 66: GSK: YoY revenue and growth rate of Ventolin 2013-2015 ($ billions) Exhibit 67: GSK: Geographical segmentation of Ventolin 2015 Exhibit 68: GSK: YoY growth and revenue of Relvar/Breo Ellipta 2014-2015 ($ millions) Exhibit 69: GSK: Geographical segmentation of Relvar/Breo Ellipta 2015 Exhibit 70: GSK: Metrics analysis Exhibit 71: Merck: YoY growth and revenue of Singulair 2013-2015 ($ millions) Exhibit 72: Merck: YoY growth and revenue of Dulera 2013-2015 ($ millions) Exhibit 73: Merck: Metrics analysis0

AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GSK, Merck, ALK-Abello, Amgen, Array BioPharma, Asmacure, Astellas Pharma, Axikin Pharmaceuticals, Chiesi Farmaceutici, Dynavax Technologies, Horizon Pharma, Hovione Scientia, Invion, Ivax, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma, Nycomed, Oxagen Limited, Palobiofarma, Pearl Therapeutics, Pharmaking, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, RSPR Pharma AB, SAMA Pharmaceuticals, Sanofi, Skyepharma, SolAeroMed, Stallergenes, Sterna Biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, Vectura, Verona Pharma, Whanin Pharmaceutical.